Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase

Jeroen T. Buijs, Kasia M. Matula, Henry Cheung, Marianna Kruithof-De Julio, Maaike H. Van Der Mark, Thomas J. Snoeks, Ron Cohen, Willem E. Corver, Khalid Mohammad, Jos Jonkers, Theresa Guise, Gabri Van Der Pluijm

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90% and 10-15% of the total cases, respectively. At the time of diagnosis and surgical resection of the primary tumour, most patients do not have clinical signs of metastases, but bone micrometastases may already be present. Our aim was to develop a novel preclinical ILC model of spontaneous bone micrometastasis. We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1(F/F);Trp53(F/F) mouse model of de novo mammary tumour formation. After surgical resection of the growing orthotopically implanted KEP cells, distant metastases were formed. In contrast to other orthotopic breast cancer models, KEP cells readily formed skeletal metastases with minimal lung involvement. Continuous treatment with SD-208 (60mg/kg per day), an orally available TGFβ receptor I kinase inhibitor, increased the tumour growth at the primary site and increased the number of distant metastases. Furthermore, when SD-208 treatment was started after surgical resection of the orthotopic tumour, increased bone colonisation was also observed (versus vehicle). Both our in vitro and in vivo data show that SD-208 treatment reduced TGFβ signalling, inhibited apoptosis, and increased proliferation. In conclusion, we have demonstrated that orthotopic implantation of murine ILC cells represent a new breast cancer model of minimal residual disease in vivo, which comprises key steps of the metastatic cascade. The cancer cells are sensitive to the anti-tumour effects of TGFβ. Our in vivo model is ideally suited for functional studies and evaluation of new pharmacological intervention strategies that may target one or more steps along the metastatic cascade of events.

Original languageEnglish
Pages (from-to)745-759
Number of pages15
JournalJournal of Pathology
Volume235
Issue number5
DOIs
StatePublished - Apr 1 2015

Fingerprint

Lobular Carcinoma
Phosphotransferases
Pharmacology
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Neoplasm Micrometastasis
Neoplasms
Ductal Carcinoma
Residual Neoplasm
Cadherins
Therapeutics
Apoptosis
Lung
Growth
SD-208

Keywords

  • breast cancer
  • invasive lobular carcinoma
  • metastasis
  • minimal residual disease
  • mouse model
  • receptor I kinase inhibitor
  • SD-208
  • TGFβ

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Buijs, J. T., Matula, K. M., Cheung, H., Kruithof-De Julio, M., Van Der Mark, M. H., Snoeks, T. J., ... Van Der Pluijm, G. (2015). Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase. Journal of Pathology, 235(5), 745-759. https://doi.org/10.1002/path.4488

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase. / Buijs, Jeroen T.; Matula, Kasia M.; Cheung, Henry; Kruithof-De Julio, Marianna; Van Der Mark, Maaike H.; Snoeks, Thomas J.; Cohen, Ron; Corver, Willem E.; Mohammad, Khalid; Jonkers, Jos; Guise, Theresa; Van Der Pluijm, Gabri.

In: Journal of Pathology, Vol. 235, No. 5, 01.04.2015, p. 745-759.

Research output: Contribution to journalArticle

Buijs, JT, Matula, KM, Cheung, H, Kruithof-De Julio, M, Van Der Mark, MH, Snoeks, TJ, Cohen, R, Corver, WE, Mohammad, K, Jonkers, J, Guise, T & Van Der Pluijm, G 2015, 'Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase', Journal of Pathology, vol. 235, no. 5, pp. 745-759. https://doi.org/10.1002/path.4488
Buijs, Jeroen T. ; Matula, Kasia M. ; Cheung, Henry ; Kruithof-De Julio, Marianna ; Van Der Mark, Maaike H. ; Snoeks, Thomas J. ; Cohen, Ron ; Corver, Willem E. ; Mohammad, Khalid ; Jonkers, Jos ; Guise, Theresa ; Van Der Pluijm, Gabri. / Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase. In: Journal of Pathology. 2015 ; Vol. 235, No. 5. pp. 745-759.
@article{69fc8d2e89af4a87b0207280d531cc61,
title = "Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase",
abstract = "Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90{\%} and 10-15{\%} of the total cases, respectively. At the time of diagnosis and surgical resection of the primary tumour, most patients do not have clinical signs of metastases, but bone micrometastases may already be present. Our aim was to develop a novel preclinical ILC model of spontaneous bone micrometastasis. We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1(F/F);Trp53(F/F) mouse model of de novo mammary tumour formation. After surgical resection of the growing orthotopically implanted KEP cells, distant metastases were formed. In contrast to other orthotopic breast cancer models, KEP cells readily formed skeletal metastases with minimal lung involvement. Continuous treatment with SD-208 (60mg/kg per day), an orally available TGFβ receptor I kinase inhibitor, increased the tumour growth at the primary site and increased the number of distant metastases. Furthermore, when SD-208 treatment was started after surgical resection of the orthotopic tumour, increased bone colonisation was also observed (versus vehicle). Both our in vitro and in vivo data show that SD-208 treatment reduced TGFβ signalling, inhibited apoptosis, and increased proliferation. In conclusion, we have demonstrated that orthotopic implantation of murine ILC cells represent a new breast cancer model of minimal residual disease in vivo, which comprises key steps of the metastatic cascade. The cancer cells are sensitive to the anti-tumour effects of TGFβ. Our in vivo model is ideally suited for functional studies and evaluation of new pharmacological intervention strategies that may target one or more steps along the metastatic cascade of events.",
keywords = "breast cancer, invasive lobular carcinoma, metastasis, minimal residual disease, mouse model, receptor I kinase inhibitor, SD-208, TGFβ",
author = "Buijs, {Jeroen T.} and Matula, {Kasia M.} and Henry Cheung and {Kruithof-De Julio}, Marianna and {Van Der Mark}, {Maaike H.} and Snoeks, {Thomas J.} and Ron Cohen and Corver, {Willem E.} and Khalid Mohammad and Jos Jonkers and Theresa Guise and {Van Der Pluijm}, Gabri",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/path.4488",
language = "English",
volume = "235",
pages = "745--759",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; The effect of pharmacological targeting TGFβ receptor i kinase

AU - Buijs, Jeroen T.

AU - Matula, Kasia M.

AU - Cheung, Henry

AU - Kruithof-De Julio, Marianna

AU - Van Der Mark, Maaike H.

AU - Snoeks, Thomas J.

AU - Cohen, Ron

AU - Corver, Willem E.

AU - Mohammad, Khalid

AU - Jonkers, Jos

AU - Guise, Theresa

AU - Van Der Pluijm, Gabri

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90% and 10-15% of the total cases, respectively. At the time of diagnosis and surgical resection of the primary tumour, most patients do not have clinical signs of metastases, but bone micrometastases may already be present. Our aim was to develop a novel preclinical ILC model of spontaneous bone micrometastasis. We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1(F/F);Trp53(F/F) mouse model of de novo mammary tumour formation. After surgical resection of the growing orthotopically implanted KEP cells, distant metastases were formed. In contrast to other orthotopic breast cancer models, KEP cells readily formed skeletal metastases with minimal lung involvement. Continuous treatment with SD-208 (60mg/kg per day), an orally available TGFβ receptor I kinase inhibitor, increased the tumour growth at the primary site and increased the number of distant metastases. Furthermore, when SD-208 treatment was started after surgical resection of the orthotopic tumour, increased bone colonisation was also observed (versus vehicle). Both our in vitro and in vivo data show that SD-208 treatment reduced TGFβ signalling, inhibited apoptosis, and increased proliferation. In conclusion, we have demonstrated that orthotopic implantation of murine ILC cells represent a new breast cancer model of minimal residual disease in vivo, which comprises key steps of the metastatic cascade. The cancer cells are sensitive to the anti-tumour effects of TGFβ. Our in vivo model is ideally suited for functional studies and evaluation of new pharmacological intervention strategies that may target one or more steps along the metastatic cascade of events.

AB - Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90% and 10-15% of the total cases, respectively. At the time of diagnosis and surgical resection of the primary tumour, most patients do not have clinical signs of metastases, but bone micrometastases may already be present. Our aim was to develop a novel preclinical ILC model of spontaneous bone micrometastasis. We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1(F/F);Trp53(F/F) mouse model of de novo mammary tumour formation. After surgical resection of the growing orthotopically implanted KEP cells, distant metastases were formed. In contrast to other orthotopic breast cancer models, KEP cells readily formed skeletal metastases with minimal lung involvement. Continuous treatment with SD-208 (60mg/kg per day), an orally available TGFβ receptor I kinase inhibitor, increased the tumour growth at the primary site and increased the number of distant metastases. Furthermore, when SD-208 treatment was started after surgical resection of the orthotopic tumour, increased bone colonisation was also observed (versus vehicle). Both our in vitro and in vivo data show that SD-208 treatment reduced TGFβ signalling, inhibited apoptosis, and increased proliferation. In conclusion, we have demonstrated that orthotopic implantation of murine ILC cells represent a new breast cancer model of minimal residual disease in vivo, which comprises key steps of the metastatic cascade. The cancer cells are sensitive to the anti-tumour effects of TGFβ. Our in vivo model is ideally suited for functional studies and evaluation of new pharmacological intervention strategies that may target one or more steps along the metastatic cascade of events.

KW - breast cancer

KW - invasive lobular carcinoma

KW - metastasis

KW - minimal residual disease

KW - mouse model

KW - receptor I kinase inhibitor

KW - SD-208

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=84924542211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924542211&partnerID=8YFLogxK

U2 - 10.1002/path.4488

DO - 10.1002/path.4488

M3 - Article

C2 - 25421310

AN - SCOPUS:84924542211

VL - 235

SP - 745

EP - 759

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 5

ER -